Author(s):
S. Arjun, M P Venkatesh, Balamuralidhara V, T M Pramod Kumar
Email(s):
venkateshmpv@jssuni.edu.in
DOI:
10.5958/0974-360X.2020.00258.9 
Address:
S. Arjun, M P Venkatesh, Balamuralidhara V, T M Pramod Kumar
Pharmaceutical Regulatory Affairs Group, Dept. of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru-570015, Karnataka, India.
*Corresponding Author
Published In:
Volume - 13,
Issue - 3,
Year - 2020
ABSTRACT:
Expedited programs is generally used in the development of drugs useful for the treatment of serious and life-threatening diseases. FDA has provided different programs such as accelerated approval, fast track, breakthrough therapy and priority review to speed up the review procedure of new drugs for the people in need. A wide range of approaches are utilized by these pathways to improve the effectiveness as well as to shorten the time required for review and also to increase the interactions between regulatory authorities and drug developers. In 2017, approximately there were 30000 recognized diseases where 6000 to 8000 are considered as rare diseases where in 70% of these are genetic in origin. It is important to understand the nature of the expedited programs and review the guidelines, since the pathways utilises range of approaches. Expedite program helps to identify the most promising therapies, promote research discoveries, and speed the FDA’s review process and development of new drugs to improve the health of people.
Cite this article:
S. Arjun, M P Venkatesh, Balamuralidhara V, T M Pramod Kumar. Expedited programs for Drug Development and Approval in USA. Research J. Pharm. and Tech 2020; 13(3):1409-1414. doi: 10.5958/0974-360X.2020.00258.9
Cite(Electronic):
S. Arjun, M P Venkatesh, Balamuralidhara V, T M Pramod Kumar. Expedited programs for Drug Development and Approval in USA. Research J. Pharm. and Tech 2020; 13(3):1409-1414. doi: 10.5958/0974-360X.2020.00258.9 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-3-63
REFERENCES:
1.
FDA guideline on - Fast
Track, Breakthrough Therapy, Accelerated Approval, Priority Review – (Accessed on
26/07/19). Available from: URL:https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review
2.
Pratik Dash,
Satyajit Behera, Dillip Kumar Mohapatra. Investigational New Drug Application Process
(IND) - As a Tool for Drug Discovery. Research J. Science and Tech. 2010; 2(3):
47-50
3.
FDA guidelines on
- Guidance for Industry Expedited Programs for Serious Conditions – Drugs and Biologics
– (Accessed on 26/07/19). Available from: URL:https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologics
4.
FDA report
on - Advancing health through innovation 2017 new drug therapy approvals - – (Accessed
on 26/07/19). Available from: URL:https://www.fda.gov/files/about%20fda/published/2017-N
ew-Drug-Therapy-Approvals-Report.pdf
5. FDA document on -Advancing health through innovation 2018
new drug therapy approvals– (Accessed on 26/07/19). Available from: URL:https://www.fda.gov/files/drugs/published/New-Drug-Therapy-Approvals-2018_3.pdf
6.
Pradeep Sahu, Neha
Pinkalwar, RavindraDhar Dubey, Shweta Paroha, Shilpi Chatterjee, Tanushree Chatterjee.
Biomarkers: An Emerging Tool for Diagnosis of a Disease and Drug Development. Asian
J. Res. Pharm. Sci. 1(1): Jan.-Mar. 2011; Page 09-16.
7.
A. Tamil Selvan, C.
Jothibaskara Mohan, S. Karpagam Kumara Sundari, R. Suthakaran. Study on Role of
Postmarketing Surveillance in New Drug Development. Asian J. Management 4(1): Jan.-Mar.
2013 page 12-15
8.
Manohar D. Kengar,
Kiran K. Patole, Akshay K. Ade, Sumesh M. Kumbhar, Chetan D. Patil, Ashutosh R.
Ganjave. Introduction to Pharmacovigilance and Monitoring. Asian J. Pharm. Res.
2019; 9(2): 116-122.
9.
Nikita R. Nikam, Rohan
R. Vakhariya, Dr. C. S. Magdum. Pharmacovigilance: An Overview. Asian J. Res. Pharm.
Sci. 2019; 9(2):107-111.
10. Archana B. Chavhan, Dipali M. Bhoi. Pharmacovigillance:
Drug Safety Monitoring. Asian J. Pharm. Tech. 2019; 9(1):49-52.
11. Swati Rawat, Akhilesh Gupta. Regulatory Requirements for
Drug Development and Approval in United States: A Review. Asian J. Pharm. Res. 1(1):
Jan.-Mar. 2011; Page 01-06.
12. Debarupa Dutta, Prithviraj Chakraborty. ORPHAN DRUGS -
ITS PROS AND CONS. Research J. Pharma. Dosage Forms and Tech. 2009; 1(2): 59-66
13. Nilima Kanwar Hada, Mahendra Singh Ashawat. Ethical Conduct
of Paediatric Clinical Trials; Issues and Challenges. Res. J. Pharm. Dosage Form.
and Tech. 6(3): July- Sept. 2014; Page 156-160.
14. Martin Kwok, Theresa Foster, Michael Steinberg. Expedited
Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
Elsevier. Sep 1, 2015 volume 37, issue 9, pages 2104-2120.